Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review
Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting a significant part of the population. The majority of AD cases occur in the elderly with a typical age of onset of the disease above 65 years. AD presents a major burden for the healthcare system and since population is...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2021.646901/full |
id |
doaj-faf14890a7014b26995694e1c87fd6c9 |
---|---|
record_format |
Article |
spelling |
doaj-faf14890a7014b26995694e1c87fd6c92021-03-18T04:17:36ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652021-03-011310.3389/fnagi.2021.646901646901Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive ReviewDavid VogrincKatja GoričarVita DolžanAlzheimer's disease (AD) is a complex neurodegenerative disease, affecting a significant part of the population. The majority of AD cases occur in the elderly with a typical age of onset of the disease above 65 years. AD presents a major burden for the healthcare system and since population is rapidly aging, the burden of the disease will increase in the future. However, no effective drug treatment for a full-blown disease has been developed to date. The genetic background of AD is extensively studied; numerous genome-wide association studies (GWAS) identified significant genes associated with increased risk of AD development. This review summarizes more than 100 risk loci. Many of them may serve as biomarkers of AD progression, even in the preclinical stage of the disease. Furthermore, we used GWAS data to identify key pathways of AD pathogenesis: cellular processes, metabolic processes, biological regulation, localization, transport, regulation of cellular processes, and neurological system processes. Gene clustering into molecular pathways can provide background for identification of novel molecular targets and may support the development of tailored and personalized treatment of AD.https://www.frontiersin.org/articles/10.3389/fnagi.2021.646901/fullAlzheimer's diseasegeneticsbiomarkermolecular pathwaysgene ontology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David Vogrinc Katja Goričar Vita Dolžan |
spellingShingle |
David Vogrinc Katja Goričar Vita Dolžan Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review Frontiers in Aging Neuroscience Alzheimer's disease genetics biomarker molecular pathways gene ontology |
author_facet |
David Vogrinc Katja Goričar Vita Dolžan |
author_sort |
David Vogrinc |
title |
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review |
title_short |
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review |
title_full |
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review |
title_fullStr |
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review |
title_full_unstemmed |
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review |
title_sort |
genetic variability in molecular pathways implicated in alzheimer's disease: a comprehensive review |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2021-03-01 |
description |
Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting a significant part of the population. The majority of AD cases occur in the elderly with a typical age of onset of the disease above 65 years. AD presents a major burden for the healthcare system and since population is rapidly aging, the burden of the disease will increase in the future. However, no effective drug treatment for a full-blown disease has been developed to date. The genetic background of AD is extensively studied; numerous genome-wide association studies (GWAS) identified significant genes associated with increased risk of AD development. This review summarizes more than 100 risk loci. Many of them may serve as biomarkers of AD progression, even in the preclinical stage of the disease. Furthermore, we used GWAS data to identify key pathways of AD pathogenesis: cellular processes, metabolic processes, biological regulation, localization, transport, regulation of cellular processes, and neurological system processes. Gene clustering into molecular pathways can provide background for identification of novel molecular targets and may support the development of tailored and personalized treatment of AD. |
topic |
Alzheimer's disease genetics biomarker molecular pathways gene ontology |
url |
https://www.frontiersin.org/articles/10.3389/fnagi.2021.646901/full |
work_keys_str_mv |
AT davidvogrinc geneticvariabilityinmolecularpathwaysimplicatedinalzheimersdiseaseacomprehensivereview AT katjagoricar geneticvariabilityinmolecularpathwaysimplicatedinalzheimersdiseaseacomprehensivereview AT vitadolzan geneticvariabilityinmolecularpathwaysimplicatedinalzheimersdiseaseacomprehensivereview |
_version_ |
1724217798463324160 |